PMID- 34065520
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210615
IS  - 2076-393X (Print)
IS  - 2076-393X (Electronic)
IS  - 2076-393X (Linking)
VI  - 9
IP  - 5
DP  - 2021 May 20
TI  - Quality Verification with a Cluster-Controlled Manufacturing System to Generate 
      Monocyte-Derived Dendritic Cells.
LID - 10.3390/vaccines9050533 [doi]
LID - 533
AB  - Dendritic cell (DC) vaccines for cancer immunotherapy have been actively 
      developed to improve clinical efficacy. In our previous report, monocyte-derived 
      DCs induced by interleukin (IL)-4 with a low-adherence dish (low-adherent 
      IL-4-DCs: la-IL-4-DCs) improved the yield and viability, as well as relatively 
      prolonged survival in vitro, compared to IL-4-DCs developed using an adherent 
      culture protocol. However, la-IL-4-DCs exhibit remarkable cluster formation and 
      display heterogeneous immature phenotypes. Therefore, cluster formation in 
      la-IL-4-DCs needs to be optimized for the clinical development of DC vaccines. In 
      this study, we examined the effects of cluster control in the generation of 
      mature IL-4-DCs, using cell culture vessels and measuring spheroid formation, 
      survival, cytokine secretion, and gene expression of IL-4-DCs. Mature IL-4-DCs in 
      cell culture vessels (cluster-controlled IL-4-DCs: cc-IL-4-DCs) displayed 
      increased levels of CD80, CD86, and CD40 compared with that of la-IL-4-DCs. 
      cc-IL-4-DCs induced antigen-specific cytotoxic T lymphocytes (CTLs) with a human 
      leukocyte antigen (HLA)-restricted melanoma antigen recognized by T cells 1 
      (MART-1) peptide. Additionally, cc-IL-4-DCs produced higher levels of IFN-gamma, 
      possessing the CTL induction. Furthermore, DNA microarrays revealed the 
      upregulation of BCL2A1, a pro-survival gene. According to these findings, the 
      cc-IL-4-DCs are useful for generating homogeneous and functional IL-4-DCs that 
      would be expected to promote long-lasting effects in DC vaccines.
FAU - Kawaguchi, Haruhiko
AU  - Kawaguchi H
AD  - Department of Regenerative Medicine, Kanazawa Medical University, Uchinada, 
      Kahoku, Ishikawa 920-0293, Japan.
FAU - Sakamoto, Takuya
AU  - Sakamoto T
AUID- ORCID: 0000-0003-2519-4510
AD  - Department of Regenerative Medicine, Kanazawa Medical University, Uchinada, 
      Kahoku, Ishikawa 920-0293, Japan.
AD  - Center for Regenerative Medicine, Kanazawa Medical University Hospital, Uchinada, 
      Kahoku, Ishikawa 920-0293, Japan.
FAU - Koya, Terutsugu
AU  - Koya T
AD  - Department of Regenerative Medicine, Kanazawa Medical University, Uchinada, 
      Kahoku, Ishikawa 920-0293, Japan.
AD  - Center for Regenerative Medicine, Kanazawa Medical University Hospital, Uchinada, 
      Kahoku, Ishikawa 920-0293, Japan.
FAU - Togi, Misa
AU  - Togi M
AUID- ORCID: 0000-0002-7424-4548
AD  - Department of Regenerative Medicine, Kanazawa Medical University, Uchinada, 
      Kahoku, Ishikawa 920-0293, Japan.
AD  - Center for Regenerative Medicine, Kanazawa Medical University Hospital, Uchinada, 
      Kahoku, Ishikawa 920-0293, Japan.
FAU - Date, Ippei
AU  - Date I
AD  - Department of Regenerative Medicine, Kanazawa Medical University, Uchinada, 
      Kahoku, Ishikawa 920-0293, Japan.
FAU - Watanabe, Asuka
AU  - Watanabe A
AD  - Department of Regenerative Medicine, Kanazawa Medical University, Uchinada, 
      Kahoku, Ishikawa 920-0293, Japan.
FAU - Yoshida, Kenichi
AU  - Yoshida K
AD  - Center for Regenerative Medicine, Kanazawa Medical University Hospital, Uchinada, 
      Kahoku, Ishikawa 920-0293, Japan.
FAU - Kato, Tomohisa
AU  - Kato T
AD  - Medical Research Institute, Kanazawa Medical University, Uchinada, Kahoku, 
      Ishikawa 920-0293, Japan.
FAU - Nakamura, Yuka
AU  - Nakamura Y
AD  - Medical Research Institute, Kanazawa Medical University, Uchinada, Kahoku, 
      Ishikawa 920-0293, Japan.
FAU - Ishigaki, Yasuhito
AU  - Ishigaki Y
AUID- ORCID: 0000-0003-1012-8430
AD  - Medical Research Institute, Kanazawa Medical University, Uchinada, Kahoku, 
      Ishikawa 920-0293, Japan.
FAU - Shimodaira, Shigetaka
AU  - Shimodaira S
AUID- ORCID: 0000-0002-6612-6912
AD  - Department of Regenerative Medicine, Kanazawa Medical University, Uchinada, 
      Kahoku, Ishikawa 920-0293, Japan.
AD  - Center for Regenerative Medicine, Kanazawa Medical University Hospital, Uchinada, 
      Kahoku, Ishikawa 920-0293, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210520
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC8160655
OTO - NOTNLM
OT  - BCL2A1
OT  - cluster control
OT  - cluster formation
OT  - dendritic cells
OT  - immunotherapy
OT  - vaccine
COIS- The authors declare no conflict of interest.
EDAT- 2021/06/03 06:00
MHDA- 2021/06/03 06:01
PMCR- 2021/05/20
CRDT- 2021/06/02 01:13
PHST- 2021/04/05 00:00 [received]
PHST- 2021/05/14 00:00 [revised]
PHST- 2021/05/17 00:00 [accepted]
PHST- 2021/06/02 01:13 [entrez]
PHST- 2021/06/03 06:00 [pubmed]
PHST- 2021/06/03 06:01 [medline]
PHST- 2021/05/20 00:00 [pmc-release]
AID - vaccines9050533 [pii]
AID - vaccines-09-00533 [pii]
AID - 10.3390/vaccines9050533 [doi]
PST - epublish
SO  - Vaccines (Basel). 2021 May 20;9(5):533. doi: 10.3390/vaccines9050533.